Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Viking Therapeutics Stock Briefly Popped Today


Shares of the developmental-stage biotech Viking Therapeutics (NASDAQ: VKTX) jumped by as much as 11.2% in pre-market action Thursday morning. The company's shares perked up in response to an intriguing top-line readout for the experimental X-linked adrenoleukodystrophy (X-ALD) drug dubbed VK0214 in a phase 1 trial.

X-ALD is an inherited disease characterized by the gradual loss of a key structural protein (myelin) encasing the nerves in the brain and spinal cord. Previously, Viking was granted orphan drug designation by the Food and Drug Administration (FDA) for VK0214 as a treatment for this often fatal genetic disorder. 

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments